RxDoctor Payments Data

Bridget Herring, NP

Family · Greenville, NCNPI 1265124192

Payments from drug & device makers

$1,332in general payments, 2019–2025

Across 80 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$279
  • AstraZeneca$192
  • Novartis$177
  • Scpharmaceuticals Inc.$121
  • Boehringer Ingelheim$102
  • Pfizer$92
  • plus $370 from 7 others

What the payments were for

  • Food & beverage$1,332100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,332 in reported general payments places this provider in the 75th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$29,691
Medicare patients
111
Services billed
348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis15$335,199
EntrestoSacubitril/Valsartan334$315,431
FarxigaDapagliflozin Propanediol196$198,590
EliquisApixaban101$92,985
JardianceEmpagliflozin89$84,918
Repatha SureclickEvolocumab22$14,217
XareltoRivaroxaban21$14,179
Bumetanide119$5,132
Torsemide96$3,276
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine15$3,173
Spironolactone328$2,007
Metoprolol Succinate175$1,893
Eplerenone28$1,457
Atorvastatin Calcium110$1,187
Carvedilol111$1,132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$92$428,184116 claims
NovartisEntresto$177$315,431334 claims
AstraZenecaFarxiga$192$198,590196 claims
Boehringer IngelheimJardiance$102$84,91889 claims
Johnson & JohnsonXarelto$78$14,17921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,522 family providers in North Carolina.

Other family in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →